Page 3 - Warren Ackerman News Today

New wave of obesity treatments has the potential to stunt more than patients' appetites

Medical nutrition for those with chronic illnesses is expected to grow to a $28 billion market by 2030, according to Barclays.

Consumer goods giant Unilever is reviving efforts to sell some of its non-core beauty and personal care brands, including Q-Tips and Impulse.

Heres how industry analysts from Wealth Club, Shore Capital, Liberum, Davy and Barclays viewed Associated British Foods performance.

GE HealthCare has joined forces with Axim Life Isotopes South Africa (Alisa) to expand provision of molecular imaging in South Africa...

The global food industry has faced accusations of greedflation amid pressure on household bills. Are the claims fair?

Analyst Warren Ackerman from Barclays research considers the stock attractive and recommends it with a Buy rating. The target price is still set at CHF 135.

In a research note, Barclays analyst Warren Ackerman has maintained his recommendation on the stock with a Neutral rating. The target price continues to be set at GBX 4300.

Unilever has reported underlying sales growth of 9.1% in H1. Heres how leading industry analysts viewed its performance.

Despite Unilevers enviable big-name-brand clout, an aggressive approach is necessary to tackle underperformance and structural problems